Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019). ClinicalTrials.gov record last updated 2026-09-25: recruiting. Enrollment is planned at 780 participants. Primary completion is estimated at 2034-02-21. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication. Registered primary measures: Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares TROP2, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads), Cisplatin.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads).
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Merck & Co. (MSD), Gemcitabine.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin.
Shares Sacituzumab tirumotecan, TROP2, Pemetrexed, Topoisomerase-I inhibitors (and ADC payloads).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/